A patient with type 2 diabetes and heart failure with reduced ejection fraction (HFrEF) would benefit most from which medication class based on current evidence?
-
A
Thiazolidinediones
-
B
SGLT-2 inhibitors
-
C
Sulfonylureas
-
D
DPP-4 inhibitors (saxagliptin)